Keros Therapeutics Files 8-K
Ticker: KROS · Form: 8-K · Filed: Dec 10, 2024 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | 8-K |
| Filed Date | Dec 10, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, regulatory-filing
TL;DR
Keros Therapeutics filed an 8-K on Dec 9th, likely a material event. Watch for details.
AI Summary
Keros Therapeutics, Inc. filed an 8-K on December 10, 2024, reporting an event that occurred on December 9, 2024. The filing pertains to 'Other Events' and 'Financial Statements and Exhibits'. Specific details regarding the nature of these events or any financial figures were not provided in the excerpt.
Why It Matters
This filing indicates a material event has occurred for Keros Therapeutics, requiring public disclosure. Investors should look for further details to understand the implications.
Risk Assessment
Risk Level: medium — An 8-K filing signifies a material event, which could be positive or negative, thus carrying medium risk until details are clarified.
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- December 9, 2024 (date) — Date of earliest event reported
- December 10, 2024 (date) — Date of report
- Lexington, Massachusetts (location) — Principal executive offices
FAQ
What specific event triggered this 8-K filing for Keros Therapeutics?
The provided excerpt does not specify the exact event, only that it falls under 'Other Events' and 'Financial Statements and Exhibits'.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on December 9, 2024.
What is the principal executive office address for Keros Therapeutics?
The principal executive offices are located at 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.
What is the SEC file number for Keros Therapeutics?
The SEC file number for Keros Therapeutics is 001-39264.
What is the standard industrial classification for Keros Therapeutics?
The standard industrial classification for Keros Therapeutics is Pharmaceutical Preparations [2834].
Filing Stats: 482 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-12-09 19:31:33
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto
Filing Documents
- kros-20241209.htm (8-K) — 36KB
- exhibit991ash2024.htm (EX-99.1) — 33KB
- 0001664710-24-000099.txt ( ) — 201KB
- kros-20241209.xsd (EX-101.SCH) — 2KB
- kros-20241209_lab.xml (EX-101.LAB) — 22KB
- kros-20241209_pre.xml (EX-101.PRE) — 13KB
- kros-20241209_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On December 9, 2024, Keros Therapeutics, Inc. (the "Company") issued a press release announcing additional data from its two ongoing Phase 2 clinical trials of elritercept (KER-050), one in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes and one in patients with myelofibrosis, at the 66th American Society of Hematology Annual Meeting and Exposition, held virtually and in person from December 7 through 10, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated December 9 , 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: December 9, 2024